Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer

Status Terminated

Clinical Trial Summary

Current therapies for Stage IV lung cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage IV lung cancer.

PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Stage IV lung cancer.

Clinical Trial Description

OVERVIEW: This is a single arm, open-label study in which patients with Stage IV lung cancer patients receive gradually escalating doses of intravenous Antineoplaston therapy (Atengenal + Astugenal) until the maximum tolerated dose is reached. Treatment continues up to12 months in the absence of disease progression or unacceptable toxicity.

OBJECTIVES:

- To determine the efficacy of Antineoplaston therapy in patients with Stage IV lung cancer, as measured by an objective response to therapy (complete response, partial response or stable disease).

- To determine the safety and tolerance of Antineoplaston therapy in patients with Stage IV lung cancer.

- To determine objective response, tumor size is measured utilizing MRI scans, which are performed every 8 weeks for the first two years, every 3 months for the third and fourth years, every 6 months for the 5th and sixth years, and annually thereafter. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00003491
Study type	Interventional
Source	Burzynski Research Institute
Contact
Status	Terminated
Phase	Phase 2
Start date	March 20, 1996
Completion date	July 31, 1998

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01228435` - IPI-504 in NSCLC Patients With ALK Translocations	Phase 2
Terminated	`NCT02128373` - A Computer-Based Intervention for Distance Caregivers of Parents With Advanced Cancer	N/A
Completed	`NCT00579215` - Lung Cancer Informational Study (LCIS)	N/A
Completed	`NCT01556191` - Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR	Phase 2
Terminated	`NCT00003495` - Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer	Phase 2
Active, not recruiting	`NCT03867175` - Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer	Phase 3
Not yet recruiting	`NCT04985357` - Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
Recruiting	`NCT06110572` - Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation	Phase 1/Phase 2
Active, not recruiting	`NCT04267575` - Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites	N/A
Not yet recruiting	`NCT06383988` - A Web-based Program to Help Caregivers of Lung Patients Learn About Available Supportive Care Resources	N/A
Completed	`NCT02606149` - Truthful Information on Chemotherapy and Its Impact on Chemotherapy at the End of Life	N/A
Completed	`NCT02693080` - CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy	Phase 1
Completed	`NCT02318771` - Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer	Phase 1
Terminated	`NCT04005144` - Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer	Phase 1
Completed	`NCT03112668` - Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners	N/A
Completed	`NCT03222258` - Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients
Completed	`NCT05025748` - Ask Questions (ASQ):Implementation of a Communication Intervention	N/A
Recruiting	`NCT05435846` - Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation	Phase 1
Terminated	`NCT02109016` - A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations	Phase 2
Terminated	`NCT00003492` - Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer	Phase 2